SITC2024: TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development

SITC 2024: Establishing a tumor cell model to evaluate the bystander effect of antibody-drug conjugate (ADC) therapies

SITC 2024: A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical efficacy and toxicity evaluation of human IL-12 analogs

SITC 2024: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy

SITC2024: The paring of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugs

BCG014: A CDH3-Targeting ADC with a Novel TOPO1 Inhibitor Payload

World ADC San Diego2024: Development of a novel bispecific ADC targeting SEZ6 and B7H3 for small cell lung cancer (SCLC)

ESDR2024：BCG028, a novel Fc-optimized fully human biparatopic OX40 antagonist for treating atopic dermatitis

ASCO 2024: A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma